Want to see HK:8329 full AI Analyst Report?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Price & Analysis

0 Followers

8329 Stock Chart & Stats

HK$0.16

>-HK$0.01(-0.63%)

At close: Jan 09 4:00 PM EST

HK$0.16

>-HK$0.01(-0.63%)

Day’s Range― - ―

52-Week RangeHK$0.09 - HK$0.18

Previous CloseN/A

Volume90.00K

Average Volume (3M)330.65K

Market Cap

HK$199.68M

Enterprise ValueHK$177.90

Total Cash (Recent Filing)HK$209.45M

Total Debt (Recent Filing)HK$73.02M

Price to Earnings (P/E)―

Beta0.18

Next Earnings

Mar 31, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield4.51%

Share Statistics

EPS (TTM)-0.02

Shares Outstanding426,000,000

10 Day Avg. Volume371,000

30 Day Avg. Volume330,653

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.37

Price to Sales (P/S)0.25

P/FCF Ratio1.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative LeverageLow leverage limits financial risk and interest burden, preserving flexibility to fund operations or investment. This provides a stabilizing foundation during periods of weak profitability, although declining equity still requires monitoring.

Improved Free Cash FlowStrong 2025 cash generation despite a reported net loss indicates favorable cash conversion and working-capital support. If sustained, this can help finance the business internally and reduce reliance on additional borrowing.

Positive Operating EarningsPositive operating earnings show that the core business remained operationally profitable before below-operating impacts. This offers a base for recovery if management can stabilize pricing, costs, and gross margins over the next several periods.

Bears Say

Revenue ContractionRepeated revenue declines indicate weak recent demand or limited growth in the existing portfolio. Without renewed volume, product adoption, or market expansion, lower sales can reduce operating leverage and make margin recovery more difficult.

Margin Compression And Net LossThe sharp deterioration from previously stronger margins and the return to a net loss reduce earnings resilience. Thin profitability leaves limited protection against pricing pressure, input-cost increases, or further revenue weakness.

Volatile Cash GenerationAlthough 2025 cash flow was strong, its history of large swings lowers confidence that the current run-rate is durable. Unpredictable cash generation can complicate investment planning and weaken the reliability of internally funded growth.

8329 FAQ

What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.18 in the past 12 months.

What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$199.68M.

When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Mar 31, 2027 which is in 221 days.

How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?

Currently, no data Available

Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?

According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.157 which represents an annual dividend yield of 4.51%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here

What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.

What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8329

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

4.51%

Trailing 12-Months

Asset Growth

-20.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.